Dogwood Therapeutics, Inc. (DWTX) Form 10-Q — May 15, 2026
Dogwood Therapeutics reported a net loss of $4.99 million for Q1 2026, driven by $2.67 million in R&D and $2.41 million in G&A expenses, with no product revenue generated to date. The company holds $13.2 million in cash, bolstered by a $12.5 million capital raise in January 2026, but explicitly states this is insufficient to fund operations beyond the fourth quarter of 2026. The filing includes a going concern warning, noting substantial doubt about the company's ability to continue as a going concern within 12 months without additional dilutive financing.
Key figures
- Revenue
- 0
- Total Debt
- 0
- Total Assets
- 95207871
- Cash Position
- 13227839
- Shares Outstanding
- 33629553
- Ga Expense Q1
- 2406587
- Rd Expense Q1
- 2669779
- Iprd Carrying Value
- 67831894
- Net Proceeds Jan2026
- 11400000
- Gross Proceeds Jan2026
- 12500000
- Goodwill Carrying Value
- 12193825
Price after filing
Close on the filing date to close N calendar days later (from $1.98). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.